Wednesday, December 06, 2017 5:22:39 PM
NASH drug developers in the red after Madrigal's mid-stage success with MGL-3196
Dec. 6, 2017 12:37 PM ET|By: Douglas W. House, SA News Editor
Investors are swarming over Madrigal Pharmaceuticals (MDGL +79.8%) after it reported positive results from a Phase 2 clinical trial assessing MGL-3196 in NASH patients. Certain would-be NASH players have been brushed aside in early trading.
Selected tickers: (MNOV +0.9%)(GLMD)(RGLS -2.2%)(ICPT +0.4%)(CNAT -2.4%)(VBLT +1.6%)(GALT -8.7%)(SHPG -1.5%)(AGN +0.3%)(HZNP -1.2%)(OTCPK:GNFTF -5%)(VKTX +2.6%)
I'm not familiar with MDGL's entry...whether it's a targeted approach for a single issue (NASH), or a multi-faceted potential like CNAT. CNAT's game is for combination therapies focused on multiple liver issues not exclusively NASH.
From CNAT Website:
FEATURED POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • Mar 27, 2024 10:52 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM